The European Medicines Agency (EMA) recently published the revised guideline on biosimilar medicines – introducing the possibility for biosimilar drug manufacturers to use a reference product approved for commercialization outside the European Economic Area (EEA). What has been the reaction from the biosimilars industry? Read more here. (Source: Federica Benassi, iHS, 12/1/14).
You are here: / / EU Following In Canada’s Footsteps On Biosimilars